Key Highlights
- Loss per share was USD 0.10 against an estimated USD 0.11 loss, and the company reported no revenue.
- Net loss was USD 20.5 million against USD 11.9 million, and Research and Development expense rose to USD 15.0 million.
- The pivotal Phase 3 study has 28 country approvals and 79 activated clinical sites for pulmonary arterial hypertension.
- The company sold 25,000,000 shares to RA Capital for gross proceeds of USD 50.0 million in July.
Inhibikase Therapeutics (NASDAQ:IKT), a clinical-stage biopharmaceutical company focused on pulmonary arterial hypertension, reported a third quarter 2026 loss of USD 0.10 per share against an estimated loss of USD 0.11. The company reported no revenue, in line with the estimate, as it remains in the clinical stage of development. Net loss was USD 20.5 million against USD 11.9 million in the prior-year quarter, when loss per share was USD 0.13.
For the nine months, net loss was USD 56.4 million against USD 35.5 million, and loss per share was USD 0.31 against USD 0.40. Cash and cash equivalents were USD 51.7 million at September 30, alongside marketable securities that the filing reports separately. Cash and cash equivalents stood at USD 139.2 million at the start of the year, and the nine-month decrease of USD 87.5 million occurred even after the financing described below.
Phase 3 Study and Spending
The company's single pivotal global Phase 3 study, IMPROVE-PAH, is enrolling patients with pulmonary arterial hypertension, and the filing describes it as the company's only pivotal study. The filing reports 28 country regulatory approvals, 79 clinical sites activated, three additional approvals pending and one country submission planned. In July 2026 the FDA's Office of Orphan Products Development granted Orphan Drug designation to its lead candidate for pulmonary arterial hypertension, following an April application. The designation applies to the active moiety, imatinib mesylate, rather than a specific formulation.
Research and development expense was USD 15.0 million against USD 7.6 million, a USD 7.4 million increase that the filing attributes mainly to USD 7.0 million of higher pulmonary arterial hypertension expense tied to the pivotal study. Spending on the risvodetinib program, which was discontinued and out-licensed, fell USD 0.3 million. Selling, general and administrative expense was USD 7.2 million against USD 5.6 million.
Financing and Cash Runway
In July 2026 the company sold 25,000,000 shares of common stock to RA Capital Management through its at-the-market Facility for gross proceeds of USD 50.0 million. For the nine months, financing included USD 52.0 million of net at-the-market proceeds and USD 1.0 million from exercise of Series A-1 warrants.
The filing states that cash, cash equivalents and marketable securities at September 30 support operations through the topline data readout in Part B of the Phase 3 study, assuming full and timely exercise of all outstanding Series A and B warrants and that development meets projected timelines. Warrants to purchase 118.7 million shares and Options to purchase 51.2 million shares were outstanding at quarter end, and the filing lists them among potentially dilutive securities.
Legal Disclosure and Items to Follow
The filing's Legal Proceedings item states the company is not currently a party to any material litigation or legal proceedings. The items to follow are enrollment progress, the pending country approvals, Warrant exercises, operating spending and the Part B readout timeline.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...